BioVersys Outlines 2024 Achievements and Financials

BioVersys AG, based in Basel, Switzerland, shared its 2024 corporate highlights and financial performance. Key developments included positive results from the BV100 Phase 2 VABP trial, showing significant efficacy and safety, and a strong proof of concept from the Alpibectir Phase 2a EBA trial. The company reported an operating income of CHF 1.2 million and a net loss of CHF 18.7 million for 2024.

Significant financial activities included a Series C financing round raising approximately CHF 15 million, complemented by USD 6 million from the Guangzhou Israeli Biotech Fund. The company's cash reserves reached CHF 32.6 million by year-end 2024. Additionally, a successful IPO on the SIX Swiss Exchange in February 2025 secured CHF 76.7 million, stabilizing finances through 2028.

Looking ahead, BioVersys plans to initiate a global Phase 3 trial for BV100 and more Phase 2 studies for Alpibectir in tuberculosis. Preclinical data generation for BV200 and BV500 will continue, alongside industry collaborations.